TECHNESCAN Drug Patent Profile

When do Technescan patents expire, and when can generic versions of Technescan launch?

Technescan is a drug marketed by Curium and Draximage and is included in five NDAs.

The generic ingredient in TECHNESCAN is technetium tc-99m pyrophosphate kit. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the technetium tc-99m pyrophosphate kit profile page.

Summary for TECHNESCAN

US Patents:	0
Applicants:	2
NDAs:	5
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	7
Patent Applications:	100
DailyMed Link:	TECHNESCAN at DailyMed

US Patents and Regulatory Information for TECHNESCAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	TECHNESCAN	technetium tc-99m oxidronate kit	INJECTABLE;INJECTION	018321-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes
Curium	TECHNESCAN MAG3	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	019882-001	Jun 15, 1990	AP	RX	Yes	Yes
Draximage	TECHNESCAN GLUCEPTATE	technetium tc-99m gluceptate kit	INJECTABLE;INJECTION	018272-001	Jan 27, 1982		DISCN	No	No
Draximage	TECHNESCAN HIDA	technetium tc-99m lidofenin kit	INJECTABLE;INJECTION	018489-001	Oct 31, 1986		DISCN	No	No
Curium	TECHNESCAN PYP KIT	technetium tc-99m pyrophosphate kit	INJECTABLE;INJECTION	017538-001	Approved Prior to Jan 1, 1982	AP	RX	No	No

Expired US Patents for TECHNESCAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Curium	TECHNESCAN	technetium tc-99m oxidronate kit	INJECTABLE;INJECTION	018321-001	Approved Prior to Jan 1, 1982
Curium	TECHNESCAN	technetium tc-99m oxidronate kit	INJECTABLE;INJECTION	018321-001	Approved Prior to Jan 1, 1982

International Patents for TECHNESCAN

See the table below for patents covering TECHNESCAN around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	48927	COMPOSITIONS FOR USE AS RADIOGRAPHIC SCANNING AGENTS
Canada	1157033	AGENT DE SCANNOGRAPHIE (RADIOGRAPHIC SCANNING AGENT)
Philippines	14568	RADIOGRAPHIC SCANNING AGENT
Germany	2960805
Japan	S6216433	WATER-SOLUBLE SUBSTANCE FOR PREPARING SCANNING AGENT FOR RADIOGRAPHY
Germany	2966389
Philippines	16295	STABILIZED RADIOGRAPHIC SCANNING AGENTS

Supplementary Protection Certificates for TECHNESCAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

TECHNESCAN Market Analysis and Financial Projection Experimental

Technetium-99m (Tc-99m) Market Dynamics and Financial Trajectory

Introduction

Technetium-99m, often referred to by its brand name Technescan, is a crucial radiopharmaceutical in the field of nuclear medicine. Its widespread use in various diagnostic procedures has made it a cornerstone in medical imaging. Here, we delve into the market dynamics and financial trajectory of Tc-99m.

Market Size and Growth

The Tc-99m market was valued at approximately USD 4.95 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.05% from 2024 to 2030, reaching nearly USD 6.54 billion by 2030[1][2].

Key Drivers of Market Growth

Several factors are driving the growth of the Tc-99m market:

Increasing Demand for Diagnostic Procedures

The rising demand for Tc-99m-based radiopharmaceuticals, particularly for cardiovascular imaging, cancer detection, and other clinical applications, is a significant driver. In the United States alone, over 40,000 Tc-99m-based imaging procedures are conducted daily, with Tc-99m used in more than 80% of all nuclear medicine procedures[1].

Advancements in Imaging Technologies

Technological advancements in imaging technologies such as Single Photon Emission Computed Tomography (SPECT) and Gamma Cameras have significantly improved the resolution and sensitivity of scans. These advancements have led to an increase in the adoption of Tc-99m for various diagnostic applications, including cardiac diagnostics and bone scans[2].

Growing Prevalence of Chronic Diseases

The high prevalence of chronic diseases such as cardiovascular diseases and cancer, particularly in regions like North America, is driving the demand for Tc-99m. For instance, in 2023, approximately 1,958,310 new cases of cancer were diagnosed in the United States, and 609,820 people died due to cancer[1].

Healthcare Infrastructure and Investments

Advanced healthcare infrastructure and significant investments in medical imaging technology in regions like North America and Europe are also contributing to market growth. The U.S. and Canada are major contributors, with substantial investments in research and development fostering innovations in Tc-99m production and application[1][4].

Market Segmentation

The Tc-99m market is segmented based on several criteria:

By Application

• Cardiovascular imaging
• Bone scans
• Respiratory imaging
• Tumor imaging
• Others

The cardiovascular segment holds the largest market share due to its critical role in myocardial perfusion imaging[1].

By Isotopic Services

• Gamma Camera
• Single Photon Emission Computed Tomography (SPECT)

By End User

• Hospitals
• Diagnostic Centers
• Others (including academic and research institutions)[1][2].

Regional Analysis

North America

North America dominates the global Tc-99m market, driven by advanced healthcare infrastructure, high prevalence of chronic diseases, and significant investments in medical imaging technology. The United States and Canada are key contributors to this region[1][2].

Europe

Europe is another significant market, with countries like Germany, France, and the U.K. driving demand for high-quality diagnostic imaging[2].

Asia-Pacific

The Asia-Pacific region, including countries like Japan, China, and India, is witnessing rapid growth due to investments in healthcare infrastructure and a growing focus on advanced diagnostics[2].

Middle East & Africa and Latin America

These regions are emerging as key markets, though they currently represent smaller shares of the overall market. Growing healthcare investments and the rising prevalence of chronic diseases are expected to create new opportunities for market expansion[2].

Technological Innovations

Technological innovations are a critical factor in the growth of the Tc-99m market:

New Production Methods

Emerging production methods, such as cyclotron and linear accelerator-based technologies, are addressing long-standing supply chain issues and reducing reliance on highly enriched uranium (HEU). For example, NorthStar Medical Radioisotopes has developed a non-uranium-based Mo-99 production technology, enhancing supply reliability and safety[4].

Automated and Remote-Controlled Production

Advancements in automated and remote-controlled radiopharmaceutical production are improving efficiency and precision, mitigating production risks, and lowering costs. These innovations are poised to drive the market by enhancing the sustainability of Mo-99 supply chains[4].

Financial Outlook

The financial trajectory of the Tc-99m market is robust:

Market Value

The market is projected to reach nearly USD 6.54 billion by 2030, growing at a CAGR of 4.05% from 2024 to 2030[1].

Revenue Projections

By 2034, the market value is expected to exceed USD 8.6 billion, driven by rising healthcare demands and advancements in medical imaging technologies[2].

Key Players and Collaborations

The market is competitive, with key players focusing on developing high-quality, cost-effective Tc-99m products. Collaborations and mergers are common, aimed at enhancing product portfolios, improving supply chains, and investing in next-generation radiopharmaceuticals. These collaborations are expected to drive market growth by ensuring the availability of high-quality Tc-99m and expanding its applications in new diagnostic areas[2].

Future Outlook

The Tc-99m market is set to continue growing due to its essential role in diagnosing chronic and non-communicable diseases, advancements in imaging technology, and a global healthcare system that increasingly relies on early detection methods. With ongoing innovations in radiopharmaceuticals and imaging technologies, Tc-99m will remain a vital tool in medical diagnostics, improving patient outcomes and revolutionizing diagnostic procedures worldwide.

"Technetium-99m's ability to identify abnormalities at the molecular level enables doctors to diagnose conditions earlier, improving patient outcomes and treatment effectiveness."[2]

Key Takeaways

• The Tc-99m market is valued at USD 4.95 billion in 2023 and is expected to grow at a CAGR of 4.05% to USD 6.54 billion by 2030.
• The market is driven by increasing demand for diagnostic procedures, advancements in imaging technologies, and the growing prevalence of chronic diseases.
• North America dominates the global market, followed by Europe and the Asia-Pacific region.
• Technological innovations in production methods and imaging technologies are critical for market growth.
• Collaborations and mergers among key players are enhancing product portfolios and supply chains.

FAQs

What is the current market size of Technetium-99m?

The Technetium-99m market was valued at approximately USD 4.95 billion in 2023[1].

What is the projected growth rate of the Technetium-99m market?

The market is expected to grow at a CAGR of 4.05% from 2024 to 2030[1].

Which region dominates the Technetium-99m market?

North America dominates the global Technetium-99m market, driven by advanced healthcare infrastructure and high prevalence of chronic diseases[1].

What are the key applications of Technetium-99m?

Key applications include cardiovascular imaging, bone scans, respiratory imaging, tumor imaging, and others[1].

How do technological innovations impact the Technetium-99m market?

Technological innovations in production methods and imaging technologies such as SPECT and Gamma Cameras are driving market growth by improving efficiency, precision, and supply chain reliability[2][4].

What is the role of Molybdenum-99 in the Technetium-99m market?

Molybdenum-99 (Mo-99) is crucial as it decays into Technetium-99m, which is used in over 80% of all nuclear medicine procedures. Innovations in Mo-99 production are enhancing the reliability and safety of Tc-99m supply chains[4].

Sources

1. Maximize Market Research: Technetium-99m Market: Industry Analysis and Forecast 2030.
2. GlobeNewswire: Technetium-99m Market Poised for Growth, Projected to Reach Over US$ 8.6 Billion by 2034.
3. Technip Energies: FY 2023 Financial Results.
4. Straits Research: Global Molybdenum 99 Market Trends, Growth, & Share-2032.